NASDAQ:ELVN | Free Cash Flow | Enliven Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2019-03-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$19.29M
2025-12-31-$15.84M
2025-03-31-$24.13M
2024-12-31-$17.2M
2024-03-31-$23.36M
2023-12-31-$12.48M
2023-03-31-$20.84M
2022-12-31-$8.15M
2022-03-31-$10.36M
2021-12-31-$12.49M
2021-03-31-$13.02M
2020-12-31-$8.27M
2020-03-31-$9.53M
2019-12-31-$8.04M
2019-03-31-$2.41M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$70.3M
2024-12-31-$73.19M
2023-12-31-$61.27M
2022-12-31-$32.08M
2021-12-31-$46.77M
2020-12-31-$37.4M
2019-12-31-$21.88M